IRIS
BELLI, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 114
EU - Europa 94
NA - Nord America 85
AF - Africa 1
Totale 294
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 85
IT - Italia 71
CN - Cina 58
SG - Singapore 50
FI - Finlandia 9
GB - Regno Unito 9
KR - Corea 5
NL - Olanda 2
DE - Germania 1
FR - Francia 1
IE - Irlanda 1
IR - Iran 1
ZA - Sudafrica 1
Totale 294
Salva come PNG Salva come JPEG
Città #
Florence 46
Shanghai 40
Singapore 31
Ogden 21
Lappeenranta 5
Milan 5
Seoul 5
Helsinki 4
Kilburn 4
London 4
Paola 4
Guangzhou 2
Hangzhou 2
Jiaxing 2
Rende 2
Alessandria 1
Chelsea 1
Cosenza 1
Dublin 1
Falkenstein 1
Heze 1
Marseille 1
Messina 1
New York 1
Plainsboro 1
Rocca d'Arazzo 1
Sesto San Giovanni 1
Shenzhen 1
Stellenbosch 1
Syracuse 1
Totale 192
Salva come PNG Salva come JPEG
Nome #
Expression of the oncoproteins p16, p53 and Ki67 as predictive value in the differentiation of low-grade intracervical neoplasms of high and low risk 17
Development and Validation of a Serum Metabolomic Signature for Endometrial Cancer Screening in Postmenopausal Women 16
Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 15
Capecitabine with/without mitomycin C: Results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma 13
Variant allele frequency: a decision-making tool in precision oncology? 12
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 11
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 11
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 11
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: Cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen) 11
Homologous recombination deficiency in triple negative breast cancer 10
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 10
Clinical significance of skin toxicity due to EGFR-targeted Therapies 10
Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden 10
Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer 9
Adjuvant treatment in biliary tract cancer: To treat or not to treat? 9
Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity 9
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: A phase II randomised trial 9
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: Not just a case? 9
Breast metastases from oligodendroglioma: An unusual extraneural spread in two young women and a review of the literature 9
Neoadjuvant therapy in resectable pancreatic cancer: A critical review 8
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046 8
Progresses toward precision medicine in RET-altered solid tumors 8
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study) 8
(Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: An open-label, randomized phase II trial 8
Targeting the microenvironment in solid tumors 8
Neo-adjuvant and adjuvant chemotherapy of gastric cancer 8
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma 8
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research 8
Baseline Tumor Size as Prognostic Index in Patients With Advanced Solid Tumors Receiving Experimental Targeted Agents 7
Evaluation of the Geographical Accessibility of Genome-Matched Clinical Trials on a National Experience 7
Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies 7
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 7
Unity is strength: One, two, or more drugs against advanced pancreatic cancer? 7
Liver toxicity in the era of immune checkpoint inhibitors: A practical approach 7
Immunomodulatory agents with antivascular activity in the treatment of non-small cell lung cancer: Focus on TLR9 agonists, IMiDs and NGR-TNF 7
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors 7
Role of taxanes in pancreatic cancer 6
The evolving landscape of ‘next-generation’ immune checkpoint inhibitors: A review 6
Translational therapies for malignant pleural mesothelioma 6
Will antiangiogenic agents be a future for mesothelioma therapy? 6
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer 6
Mesoteliona Pleurico 6
Malignant pleural mesothelioma: Current treatments and emerging drugs 6
Second-line therapy in advanced biliary tract cancer: What should be the standard? 6
Antiangiogenic strategies in breast cancer management 6
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population 5
Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current Landscape of Immune Co-Inhibitory Receptor Targeting 5
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors 5
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions 5
Tumori del polmone 5
Malignant Mesothelioma 4
A demand-offer critical analysis of current drug development. Phase I drugs versus TCGA sequencing data 4
Mesotelioma Pleurico 1
Totale 427
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.683
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023194 0 0 0 0 0 0 0 0 140 5 49 0
2023/2024200 5 1 27 8 15 6 8 32 35 13 14 36
2024/202533 33 0 0 0 0 0 0 0 0 0 0 0
Totale 427